Lentiviral Gene Therapy Stabilizes Patients With MPS1H


Follow-up data up to 3 years showed supraphysiologic levels of blood IDUA and decrease of GAGs.

Patients with mucopolysaccharidosis type 1 Hurler (MPS1H) syndrome treated with α-Liduronidase (IDUA)-encoding lentiviral-transduced autologous hematopoietic stem and progenitor cells showed metabolic correction and clinical benefit with a manageable safety profile.

These new data, from a phase 1/2 trial (NCT03488394), were presented at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany, by Francesca Tucci, MD, staff pediatrician, clinical research unit, IRCCS San Raffaele.

“MPS1H is a rare lysosomal storage disorder caused by a defect in the IDUA gene leading to glycosaminoglycans (GAGs) accumulation in multiple organs and tissues, particularly in the skeleton and central nervous system (CNS),” Tucci and colleagues wrote.“Allogeneic hematopoietic stem cell transplantation +/- pre-/peritransplant enzyme replacement therapy represents the standard treatment, but skeletal and neurocognitive manifestations still progress over time.”

The updated data are from 6 male and 2 female patients that lacked a non-heterozygous-HLA-matched donor and displayed IQ/DQ>70. The patients had a median age of 22 months (range, 14-34) at the time of treatment. Five participants that were positive for anti-IDUA antibodies before gene therapy cleared them within 3 months after infusion and remained negative at the last follow-up.

READ MORE: Expert Insights on Gene Therapy for International Batten Awareness Day

The study was primarily evaluating blood IDUA up to supraphysiologic levels at 1 year and 3 years post gene therapy infusion. Secondary and exploratory outcomes were assessing clearance of GAGs in urine and cerebrospinal fluid (CSF), radiological parameters (X-rays and MRI for the hip and the spine), and skeletal and motor development as assessed by clinical and functional scales. These scales were growth and measures of thoracolumbar kyphosis for skeletal outcomes and Peabody motor scale and joint range of motion(ROM) for functional outcomes. Hip dysplasia (HD) was evaluated in 14 hips of 7 patients, excluding 1 that had bilateral hip dislocation already present before gene therapy.

The 7 evaluable participants at 3 years had sustained engraftment of gene-corrected cells with a median 1.17 vector count number per genome (range, 0.13-3.85) in peripheral blood mononuclear cells and persistent supraphysiologic blood IDUA activity (median, 133.4 µmol/L/h; range, 38.9-151.6), above the 97.5th percentile of age-matched healthy children. These patients also had urinary GAG levels at normal or near normal levels at 3 years post-infusion. In all patients, the gene therapy was well-tolerated and CSF IDUA activity was detectable at 3 months and remained stable over time while GAGs decreased up to 3 years after infusion in 6 evaluable patients.

Investigators found that, after adjusting for age and gender, patients showed growth within the normal range of healthy children and reduction or stability in clinical measures of sitting and standing kyphosis. Participants also exhibited progressive motor skill acquisition, with the best outcomes in shoulder mobility among ROM examined. HD progressed in 1 of 14 hips assessed and spine MRI revealed stability in typical MPS1H features at latest follow-up.

“These data show extensive metabolic correction and initial clinical response after GT and a favorable safety profile, highlighting its therapeutic potential for MPSIH treatment. A longer follow-up is needed to draw definitive conclusions on the impact of GT on MPSIH manifestations in the long term,” Tucci and colleagues concluded.

Click here for more coverage of EHA 2023

Tucci F, Consiglieri G, Filisetti C, et al. Interim analysis of first in human phase 1-2 clinical trial of ex-vivo gene therapy for Hurler syndrome: An update at 3 year follow-up. Presented at: EHA 2023 Congress; June 8-11; Frankfurt, Germany. Abstract #P1392
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.